Article
Plant Sciences
Yan-fang Deng, Qian-qian Xu, Tian-qi Chen, Jia-xiong Ming, Ya-fen Wang, Li-na Mao, Jia-jun Zhou, Wei-guang Sun, Qun Zhou, Hong Ren, Yong-hui Zhang
Summary: This study reveals that kinsenoside (KD) can alleviate non-alcoholic steatohepatitis (NASH) by inhibiting the NF-Kappa B/NLRP3 signaling pathway. KD shows hepatoprotective properties and has the potential to be a novel and effective drug for treating NASH.
Article
Cell Biology
Anding Wu, Mao Ye, Tengfei Ma, Zhigang She, Ruyan Li, Hongjie Shi, Ling Yang, Maolin Yi, Huoping Li
Summary: Nonalcoholic fatty liver disease (NAFLD) is a significant contributor to cardiovascular diseases, affecting a quarter of the global population. This study revealed that the expression of TBC1 domain family member 25 (TBC1D25) is upregulated in NAFLD/NASH. TBC1D25 deficiency worsened hepatic steatosis, inflammation, and fibrosis in NASH, while its overexpression inhibited NASH responses.
JOURNAL OF CELLULAR PHYSIOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Xiaoling Li, Mengjiao Yang, Hang Sun, Md Reyad ul Ferdous, Ling Gao, Jiajun Zhao, Yongfeng Song
Summary: Cyclophilin D (CypD) can improve hepatic steatosis and nonalcoholic steatohepatitis (NASH) by reducing the excess opening of the membrane permeability transition pore (mPTP). It significantly improves lipid deposition and inflammatory symptoms.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Article
Biochemistry & Molecular Biology
Sandra Torres, Maximilian J. Brol, Fernando Magdaleno, Robert Schierwagen, Frank E. Uschner, Sabine Klein, Cristina Ortiz, Olaf Tyc, Nadine Bachtler, James Stunden, Damien Bertheloot, Ana Kitanovic, Brian Sanchez, Jacob Schrum, William R. Roush, Luigi Franchi, Kate Byth, Eicke Latz, Jonel Trebicka
Summary: IFM-514 effectively reduced liver inflammation and fibrosis, with mild effects on liver steatosis in an experimental murine NASH model. Blocking NLRP3 may be a promising therapeutic strategy for NASH patients.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Review
Medicine, General & Internal
Abdulrahman Ismaiel, Daniel-Corneliu Leucuta, Stefan-Lucian Popa, Dan L. Dumitrascu
Summary: After analyzing the role of visfatin in nonalcoholic fatty liver disease, it was found that visfatin levels are not associated with NAFLD, presence or severity of hepatic steatosis, liver fibrosis, lobar inflammation, NASH, and gender.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Carmen Fierbinteanu-Braticevici, Vlad-Teodor Enciu, Ana-Maria Calin-Necula, Ioana Raluca Papacocea, Alexandru Constantin Moldoveanu
Summary: This study compared the methacetin breath test (MBT) and octanoate breath test (OBT) in detecting patients with steatohepatitis and estimating fibrosis. Both tests were able to differentiate patients with simple steatosis from NASH and stratify patients with significant fibrosis and cirrhosis. These breath tests are potentially useful tools in assessing patients with NAFLD.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Endocrinology & Metabolism
P. Comeglio, E. Sarchielli, S. Filippi, I Cellai, G. Guarnieri, A. Morelli, G. Rastrelli, E. Maseroli, S. Cipriani, T. Mello, A. Galli, B. J. Bruno, K. Kim, K. Vangara, K. Papangkorn, N. Chidambaram, M. Patel, M. Maggi, L. Vignozzi
Summary: The study shows that LPCN 1144 can improve HFD-induced hepatic fibrosis and NASH biochemical, biomolecular, and histochemical features.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2021)
Review
Biochemistry & Molecular Biology
Patrice Marques, Vera Francisco, Laura Martinez-Arenas, Angela Carvalho-Gomes, Elena Domingo, Laura Piqueras, Marina Berenguer, Maria-Jesus Sanz
Summary: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease in Western countries, affecting about 25% of adults. It encompasses a range of liver diseases characterized by abnormal fat accumulation in the liver tissue, which can progress to inflammation and damage. This can ultimately lead to irreversible conditions like cirrhosis and hepatocarcinoma, resulting in high mortality rates and economic burden. Understanding the immune status of NAFLD patients is crucial for therapeutic approaches, early diagnosis, and prevention.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Veeral H. Ajmera, Edward R. Cachay, Christian B. Ramers, Shirin Bassirian, Seema Singh, Richele Bettencourt, Lisa Richards, Gavin Hamilton, Michael Middleton, Katie Fowler, Claude Sirlin, Rohit Loomba
Summary: This study aimed to identify the optimal threshold of CAP for detecting liver fat among PLWH, with 285 dB/m identified as a potential cut-point for correctly identifying HIV-associated NAFLD. This cut-point is similar to those for primary NAFLD and may be incorporated into routine care to identify patients at risk for HIV-associated NAFLD.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Nutrition & Dietetics
Jyothi Padiadpu, Melinda H. Spooner, Zhipeng Li, Nolan Newman, Christiane V. Lohr, K. Denise Apperson, Amiran Dzutsev, Giorgio Trinchieri, Natalia Shulzhenko, Andrey Morgun, Donald B. Jump
Summary: Nonalcoholic fatty liver disease (NAFLD) is a global health problem. This study identified early gene indicators contributing to the onset and progression of NAFLD. Transcriptomic analysis revealed early onset changes in gene expression that developed before any evidence of NALFD or NASH was observed. These early markers of disease provide potential targets for early therapeutic intervention and prevention of disease progression.
FRONTIERS IN NUTRITION
(2023)
Article
Oncology
Nicholas D. Johnson, Xiumei Wu, Christopher D. Still, Xin Chu, Anthony T. Petrick, Glenn S. Gerhard, Karen N. Conneely, Johanna K. DiStefano
Summary: An epigenome-wide analysis of 325 individuals with NAFLD identified 7 CpG sites associated with fibrosis. Gene expression at 288 genes was found to be associated with DNAm at these fibrosis-related CpGs. DNAm-based estimates of cell-type proportions showed changes in natural killer cells and epithelial cell proportions with disease stage. An elastic net regression model predicted fibrosis with a sensitivity of 0.93, suggesting DNAm as a potential biomarker for NAFLD fibrosis.
CLINICAL EPIGENETICS
(2021)
Article
Medicine, General & Internal
Feng Liu, Lai Wei, Wei Qiang Leow, Shu-Hong Liu, Ya-Yun Ren, Xiao-Xiao Wang, Xiao-He Li, Hui-Ying Rao, Rui Huang, Nan Wu, Aileen Wee, Jing-Min Zhao
Summary: This study demonstrates that the qFIBS technique derived from adult NASH can effectively distinguish different histological grades of steatosis and fibrosis in pediatric NASH.
FRONTIERS IN MEDICINE
(2022)
Article
Medicine, General & Internal
Yongin Cho, Hyungjin Rhee, Young-eun Kim, Minyoung Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Jin-Young Choi, Yong-ho Lee
Summary: This study aimed to evaluate the efficacy of ezetimibe plus rosuvastatin in reducing liver fat in NAFLD patients. The results showed that combination therapy significantly reduced liver fat measured by MRI-PDFF, and ezetimibe was particularly effective in patients with higher body mass index and type 2 diabetes.
Article
Multidisciplinary Sciences
Joaquin Perez-Schindler, Elyzabeth Vargas-Fernandez, Bettina Karrer-Cardel, Danilo Ritz, Alexander Schmidt, Christoph Handschin
Summary: This study comprehensively profiles the transcriptional response to lipotoxicity in hepatocytes by integrating transcriptomic, proteomic, and chromatin accessibility analyses. It reveals transcription factor networks deregulated by NASH and lipotoxicity and validates the predictions by genetic deletion of MAFK and TCF4. The results provide insights into cell stress mitigation, cell survival, growth, and the molecular mechanisms of NASH.
SCIENTIFIC REPORTS
(2022)
Article
Gastroenterology & Hepatology
Jun Wang, Anna H. Wu, Frank Z. Stanczyk, Jacqueline Porcel, Mazen Noureddin, Norah A. Terrault, Lynne R. Wilkens, Veronica Wendy Setiawan
Summary: Findings from a large multiethnic study support the concept that menstrual and reproductive factors, as well as the use of exogenous hormones, are associated with the risk of NAFLD.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)